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Purpose: The short-term safety and efficacy of zoledronic
acid for the treatment of skeletal metastasis was evaluated in
patients with hormone-refractory prostate cancer. Patients and
Methods: A total of 19 hormone-refractory prostate cancer
patients with bone metastases were enrolled. All patients
received up to six infusions of zoledronic acid (4 mg, given
intravenously over 15 minutes, every 3 - 4 weeks). Safety was
assessed by monitoring a`dverse events and serum creatinine
levels. Efficacy was assessed by monitoring skeletal-related
events, brief pain inventory score, quality of life score, type
of pain medication, and analgesic score. Mean age of patients
was 67.3 years (46 - 86 years), mean time from diagnosis of
bone metastases was 27.6 months (0 -117 months), and mean
time from diagnosis of hormone-refractory disease was 7.5
months (0 - 26 months). Results: There was no clinically
significant change in serum creatinine levels. Eleven adverse
events (musculoskeletal disorders and systemic disorders) in
8 patients were classed as having a possible relationship to
study drug. Fifteen patients completed six courses of zoledronic
acid infusion. There were no significant changes in the brief
pain inventory composite scores, quality of life questionnaire
scores or analgesic score. No new skeletal-related events
developed during the treatment period. Conclusion: Zoledronic
acid administered in this study as a 15-minute infusion
demonstrated an acceptable and well-known safety profile in
patients with refractory prostate cancer with bone metastases.
However, prospective placebo- controlled clinical trials are
required to elucidate the efficacy of zoledronic acid.
Key Words: Prostatic neoplasms, neoplasm metastasis,
zoledronic acid
INTRODUCTION
Every year, half a million men are diagnosed
with prostate cancer worldwide and more than
two hundred thousand die of this disease.
1 The
majority of patients (65 - 75%) with advanced
prostate cancer characteristically develop bone
metastases to the spine, pelvis and ribs, and most
of these patients experience skeletal-related events
(SREs), such as pathological bone fractures, spinal
cord compression or debilitating bone pain.
2
Therefore, the occurrence of SREs is one of the
most important factors that can impact on a
patient’s quality of life.
The older a patient is at prostate cancer diagnosis,
the more likely hormone therapy and bone
metastases will contribute to bone loss leading to
SREs. In the US, bone loss is prevalent among 1.5
million men aged over 65 years.
3 In addition,
approximately 33% of all hip fractures occur in
men, and the mortality rate due to hip fractures
in men is known to be twofold greater than that
in women.
4 Sometimes patients with prostate
cancer have pre-existing osteopenia and bone loss
before the start of hormone therapy,
5,6 which
places them at greater risk of developing SREs
and bone loss due to primary hormone therapy.
4
Long-term androgen deprivation therapy (ADT)
confers a significant decrease in bone mineral
density (BMD),
4 due to a decrease in the conversion
of androgen to estrogen; estrogen plays a vital role
in inhibiting bone resorption and sustaining
BMD.
7,8 Morote et al.
9 observed significant bone
loss in up to half the number of patients treated
with ADT for more than 5 years, and duration of
ADT correlated with a decline in BMD and an
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increase in the relative risk of hip fractures.
Although medical advances in the treatment of
advanced prostate cancer have prolonged life
expectancy, most patients may develop bone
metastases resulting in significant skeletal compli-
cations.
2 Moreover, the relatively long survival
time when compared to other malignancies may
increase the incidence of SREs, which significantly
reduce quality of life in patients with prostate
cancer.
10
Zoledronic acid is a third generation bispho-
sphonate containing a heterocyclic imidazole group
on the side chain. It is 40 to 850 times more potent
than pamidronate, a pyrophosphate derivative that
used to be the sole agent available to treat skeletal
complications related to cancer. In Europe and the
US it is the only drug approved for prostate
cancer with bone metastases and is used for the
relief of bone pain associated with cancer
metastasized to bone, as well as hypercalcemia of
malignancy. Zoledronic acid is the most potent
inhibitor of bone resorption among the bisphos-
phonates available to date.
11-13
This study, the first of its kind in Korea, has
been conducted to evaluate the short-term safety
and efficacy of zoledronic acid in patients with
hormone-refractory prostate cancer with bone
metastases.
PATIENTS AND METHODS
Patients
Patients aged 18 years with histologically
confirmed prostate cancer refractory to hormone
therapy with bone metastases were enrolled.
Hormone-refractory prostate cancer was defined
as presence of biochemical or clinical progression
despite serum testosterone levels closer to
castration levels, and evidence of persistent
progression after discontinuation of anti-androgen
agents for at least 4 weeks. Patients were also
required to have 1 bone lesions associated with
prostate cancer, bone metastases as assessed by
simple bone radiography or bone scan, and
Eastern Cooperative Oncology Group (ECOG)
performance status score of 2. The Institutional
Review Board at each participating hospital
approved the study protocol and patients signed
a written consent form.
Exclusion criteria included patients with
abnormal renal function (serum creatinine levels
1.5 times greater than the upper normal limit or
creatinine clearance < 60 mL/min), corrected
serum calcium concentration < 8.0 mg/dL (< 2.0
mmol/L) or 12 mg/dL ( 3.00 mmol/L), clinical
symptoms of brain metastasis, or a history of
allergy to zoledronic acid or other bispho-
sphonates. Patients were also excluded if they had
received any other investigational study drugs
within 30 days prior to the first infusion of
zoledronic acid, had received radiation therapy to
bone within 3 months before the first infusion of
zoledronic acid, or had received a bisphosphonate
for the treatment of other diseases such as
osteoporosis within 2 years before the start of the
study.
Study design
This was a prospective, multi-centre, open-label
study. Enrolled patients received up to six
infusions of zoledronic acid (4 mg, diluted in 100
mL calcium-free solution e.g. 0.9% w/v sodium
chloride), as a 15-minute infusion every 3 -4 weeks.
All patients were given a calcium supplement
(500- 600 mg) and multi-vitamins containing
vitamin D (400 - 500 IU) once daily.
Safety assessments
To evaluate kidney function, serum creatinine
levels were measured prior to each infusion.
Serum creatinine levels were measured pre- and
post-dose. Adverse events (AEs) were monitored
throughout the study and were evaluated
according to incidence and severity. Any follow-
up action taken to treat AEs was recorded by the
treating physician. The severity of an AE was
assessed based on Common Terminology Criteria
for Adverse Events (National Cancer Institute
v3.0) using a grading scale of 0 (no adverse event),
to 5 (death related to an adverse event),
14 and
relationship to the study drug.
Efficacy assessments
Pain assessments
Bone pain was assessed using the brief painZoledronic Acid in Prostate Cancer
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inventory (BPI) short form.
15 A composite pain
score was used, calculated as a mean of the scores
for questions 3, 4, 5 and 6. Changes in the com-
posite pain scores pre- and post-treatment were
determined and statistical analysis performed
using a linear mixed model.
Skeletal-related events (SREs)
SREs were defined as pathological bone frac-
tures, spinal cord compression, surgery or radio-
therapy to bone, or hypercalcemia. New cases of
pathological bone fractures involving bones other
than vertebrae that were secondary to minor
injury were detected by patient’s self-report and
confirmed by radiography. Radiography was
mandatory at the screening visit and the final
visit, and was also performed whenever clinically
indicated. Hypercalcemia was defined as a
corrected serum calcium level of 12 mg/dL (
3.00 mmol/L), or a corrected serum calcium level
< 12 mg/dL (< 3.00 mmol/L) with the presence of
symptoms, or a need for treatment other than
hydration. SREs were evaluated at each visit.
Quality of life assessments
The Functional Assessment of Cancer Therapy-
General (FACT-G) questionnaire was administered
at screening, at the fourth infusion of zoledronic
acid and at the final visit.
16 Quality of life scores
representing four questionnaire subscales were
evaluated, as well as changes in scores for each
subscale. Quality of life scores at the fourth
infusion of study drug and at the final visit were
compared with those at screening using a paired
t-test. The higher FACT-G scores the better the
patient’s quality of life.
Analgesic scores
Analgesic use was recorded pre- and post-
zoledronic acid infusion (at screening, at each
infusion, and at the final visit). Analgesic scores
were classified into four categories of analgesics,
‘minor analgesics (eg, aspirin or acetaminophen)’
(score 1), ‘tranquilizers’ (score 2), ‘mild opioids
(eg, oxycodone)’ (score 3), and ‘strong opioids (eg,
morphine)’ (score 4).
17 An analgesic score of ‘0’
was assigned when no analgesic was administered,
and a higher score obtained when two or more
categories of analgesics were administered. At
each visit analgesic scores were calculated by
determining analgesics used since the last visit. A
non-parametric, paired 2-sample Wilcoxon analysis
was used to analyze changes in analgesic scores
before and after treatment. The statistical analyses
in this study were performed using SAS Version
8.0.
RESULTS
A total of 19 patients were eligible for the study.
All patients received at least one dose of
zoledronic acid and were included in the safety
analysis. Fifteen (78.9 %) patients who completed
the study were included in the efficacy analysis.
Four patients were excluded from the efficacy
analysis for the following reasons: withdrawal of
informed consent (2 patients); study protocol
violation (1 patient); and adverse event, Grade 3
myalgia related to study drug (1 patient).
Mean age of patients was 67.3 ± 9.6 years (range
46.3-85.6 years), the duration of prostate cancer
(time from diagnosis of prostate cancer to first
infusion of zoledronic acid) was 32.6 ± 24.6
months (range 7 - 117 months), and the duration
of bone metastases (time from diagnosis of bone
metastases to the first infusion of zoledronic acid)
was 27.6 ± 26.5 months (range 0 - 117 months). The
time from diagnosis of hormone refractory
prostate cancer to the first infusion of zoledronic
acid was 7.5 ± 9.1 months (range 0 - 26 months).
During the study, 10 (52.6%) patients received
ADT and 9 (47.4%) patients received ADT in
conjunction with cytotoxic chemotherapy. Mean
number of zoledronic acid infusions administered
was 5.3 ± 1.5 (range 1 - 6).
Safety analysis
Changes in serum creatinine levels from
screening to final visit increased by < 0.5 mg/dL
in 18 (94.7%) patients. For one patient serum
creatinine was elevated by 0.5 - 1.0 mg/dl after
completion of the study, but returned to within
the normal range during follow-up.
The 11 AEs with a possible relationship to study
drug occurred in 8 (42.1%) patients. No AEs were
recorded with a ‘probable’ or ‘definite’ relation-Sung Joon Hong, et al.
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ship to study drug. These AEs included muscul-
oskeletal disorders, such as arthralgia, myalgia or
back pain (9 AEs, grades 1, 2, and 3 in 6 patients),
and systemic disorders, such as fever or malaise
(2 AEs, grade 2 in 2 patients). Of these 8 patients,
permanent discontinuation of study drug was
required for 1 patient (Grade 3 myalgia), 3 patients
were managed with concomitant medication, and
no intervention was required for the other 4
patients.
Efficacy analysis
Efficacy was assessed in 15 patients who
completed the study. There was no statistically
significant difference between the composite pain
scores at screening and at each infusion. Among
patients who had a composite pain score > 0 at the
first infusion of zoledronic acid, there was a trend
towards a decrease in pain after the third infusion
(Fig. 1), but this was not statistically significant.
SREs prior to zoledronic acid infusion were
reported in 3 (20.0%) patients, but none of the
patients developed new SREs.
There was a trend towards a decrease in FACT-G
overall scores but this was not statistically
significant. When subscales at the first infusion of
zoledronic acid were compared with those at the
final infusion, physical (p = 0.042) and functional
(p = 0.017) subscales showed a statistically signi-
ficant decrease. Changes in social or familial and
the emotional subscales were not statistically
significant (Table 1).
The proportion of patients using analgesics
increased from 26.3% at screening to 35.1% during
follow-up, but there was a trend towards a
decrease in the use of narcotic analgesics (Table 2).
When analgesic scores at the time of screening
were compared with those at each infusion, there
Table 1. Functional Assessment of Cancer Therapy-General (FACT-G) Scores
n Mean ± SD Difference ± SD p value
Total Infusion 1 15 79.44 ± 18.87
Infusion 4 15 75.43 ± 19.04 - 4.00 ± 13.08 0.253
Final 14 72.81 ± 20.49 - 9.52 ± 18.62 0.071
Physical Infusion 1 15 23.13 ± 5.41
Infusion 4 15 22.27 ± 5.91 - 0.87 ± 2.75 0.241
Final 14 21.21 ± 6.41 - 2.79 ± 4.63 0.042
Social/familial Infusion 1 15 19.48 ± 5.09
Infusion 4 15 18.03 ± 7.94 - 1.44 ± 7.50 0.461
Final 14 18.67 ± 6.61 - 1.06 ± 5.82 0.505
Emotional Infusion 1 15 16.43 ± 5.48
Infusion 4 15 16.60 ± 4.85 0.17 ± 6.04 0.911
Final 14 17.43 ± 4.77 0.40 ± 7.36 0.841
Functional Infusion 1 15 20.40 ± 7.43
Infusion 4 15 18.53 ± 7.00 - 1.87 ± 4.96 0.166
Final 14 15.50 ± 8.64 - 6.07 ± 8.36 0.017
SD, standard deviation.
Fig. 1. Change of brief pain inventory composite scores.Zoledronic Acid in Prostate Cancer
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was no significant difference. For patients who
had scores > 0 at the time of screening, there was
a trend towards a decrease in analgesic score after
the second infusion, but this was not statistically
significant (Fig. 2.).
DISCUSSION
Bone lesions in patients with prostate cancer and
bone metastases are characterized by osteoblastic
lesions but are also associated with osteolytic
activity resulting in a drastic decline in bone
remodeling and significant bone loss.
18 Escalated
Table 3. Functional Assessment of Cancer Therapy-General (FACT-G) Scores
n Mean ± SD Difference ± SD p value
Total Infusion 1 15 79.44 ± 18.87
Infusion 4 15 75.43 ± 19.04 - 4.00 ± 13.08 0.253
Final 14 72.81 ± 20.49 - 9.52 ± 18.62 0.071
Physical Infusion 1 15 23.13 ± 5.41
Infusion 4 15 22.27 ± 5.91 - 0.87 ± 2.75 0.241
Final 14 21.21 ± 6.41 - 2.79 ± 4.63 0.042
Social/familial Infusion 1 15 19.48 ± 5.09
Infusion 4 15 18.03 ± 7.94 - 1.44 ± 7.50 0.461
Final 14 18.67 ± 6.61 - 1.06 ± 5.82 0.505
Emotional Infusion 1 15 16.43 ± 5.48
Infusion 4 15 16.60 ± 4.85 0.17 ± 6.04 0.911
Final 14 17.43 ± 4.77 0.40 ± 7.36 0.841
Functional Infusion 1 15 20.40 ± 7.43
Infusion 4 15 18.53 ± 7.00 - 1.87 ± 4.96 0.166
Final 14 15.50 ± 8.64 - 6.07 ± 8.36 0.017
SD, standard deviation.
Table 2. The Type of Pain Medication Administered During Treatment
None Minor analgesics Tranquillizers Mild opioids Strong opioids Total
n % n % n % n % n % n %
Infusion 1 11 73.3 1 6.6 0 0.0 3 20.0 0 0.0 15 100
Infusion 2 9 60.0 4 26.6 0 0.0 2 13.3 0 0.0 15 100
Infusion 3 12 80.0 2 13.3 0 0.0 1 6.6 0 0.0 15 100
Infusion 4 11 73.3 3 20.0 0 0.0 1 6.6 0 0.0 15 100
Infusion 5 11 73.3 3 20.0 0 0.0 1 6.6 0 0.0 15 100
Infusion 6 9 60.0 4 26.6 0 0.0 1 6.6 1 6.6 15 100
Final 9 64.9 4 28.5 0 0.0 1 7.1 0 0.0 14 100
Fig. 2. Change of mean analgesic scores.Sung Joon Hong, et al.
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osteoclast activity combined with osteoblastic
lesions justify the use of bisphosphonates, which
are potent inhibitors of osteoclasts.
19
Previous studies have demonstrated that
bisphosphonates such as etidronate, clodronate
and pamidronate provide a decrease in bone pain,
and in the use of analgesics for patients with
hormone-refractory prostate cancer and bone
metastases.
20 However, these studies were not
placebo-controlled, and because of the transient
effects of the bisphosphonates, no firm con-
clusions could be drawn. Moreover, controlled
studies with clodronate and pamidronate have not
been able to demonstrate a statistically significant
decrease in pain, or in the use of analgesics.
20
Conversely, a large placebo-controlled study
evaluating the efficacy of zoledronic acid in
patients with hormone-refractory prostate cancer
and bone metastases demonstrated that the
treatment group had a significant decrease in
bone pain and SREs, such as pathological bone
fractures, spinal cord compression and bone
radiotherapy compared with the placebo group.
21
BPI composite pain scores increased in both the
placebo and treatment groups, but this increase
was significantly less in the treatment group, and
its effect was sustained for up to 24 months.
19
SREs occurred in 38% of patients in the treatment
group and 49% in the placebo group with a
significant decrease of 22%. The median time to
the onset of SREs was 321 days in the placebo
group and 488 days in the treatment group
indicating a delay of nearly 5 months in the onset
of SREs for patients who received zoledronic acid.
Zoledronic acid was, therefore, considered to play
an important role in stabilizing bones by delaying
accumulation of unstable bones.
11-13,22,23
Safety analyses in cancer patients with bone
metastases have demonstrated the stability of
zoledronic acid in blood and urine, with no
significant changes in estimated creatinine
clearance.
24,25 Our study also showed that any
change in serum creatinine level occurred within
an acceptable range, with no clinical impact. A
15-minute intravenous infusion of 4 mg zoledronic
acid is superior in terms of safety and efficacy, and
Table 4. The Type of Pain Medication Administered During Treatment
None Minor analgesics Tranquillizers Mild opioids Strong opioids Total
n % n % n % n % n % n %
Infusion 1 11 73.3 1 6.6 0 0.0 3 20.0 0 0.0 15 100.0
Infusion 2 9 60.0 4 26.6 0 0.0 2 13.3 0 0.0 15 100.0
Infusion 3 12 80.0 2 13.3 0 0.0 1 6.6 0 0.0 15 100.0
Infusion 4 11 73.3 3 20.0 0 0.0 1 6.6 0 0.0 15 100.0
Infusion 5 11 73.3 3 20.0 0 0.0 1 6.6 0 0.0 15 100.0
Infusion 6 9 60.0 4 26.6 0 0.0 1 6.6 1 6.6 15 100.0
Final 9 64.9 4 28.5 0 0.0 1 7.1 0 0.0 14 100.0
Table 5. Mean Analgesic Scores on Each Infusion Period
Infusion n Score (mean ± SD) p value
Infusion 1 15 0.67 ± 1.23
Infusion 2 15 0.67 ± 1.05 1.000
Infusion 3 15 0.33 ± 0.82 0.265
Infusion 4 15 0.40 ± 0.83 0.389
Infusion 5 15 0.40 ± 0.83 0.389
Infusion 6 15 0.73 ± 1.22 0.864
Final 14 0.50 ± 0.86 1.000Zoledronic Acid in Prostate Cancer
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supplementation with calcium and vitamin D is
recommended.
10,26,27 All patients in our study were
supplemented with calcium and vitamin D, and no
side effects due to hypocalcemia were recorded.
Adverse events occurred in 14 (73.7%) patients.
The majority (64.9%) of AEs were mild. Eleven
AEs in 8 (42.1%) patients were classed as having
a ‘possible’ relationship to zoledronic acid. The
most common AEs related to zoledronic acid are
known to be fatigue, anemia, myalgia, fever and
edema on the lower extremities.
26 During the
study, 9 AEs (musculoskeletal disorders), such as
arthralgia, myalgia or back pain and 2 AEs
(systemic disorders), such as fever or malaise were
recorded. Meanwhile, the long-term side-effect and
possible complications, such as osteonecrosis of
jaw, have not been fully evaluated in this study.
28
The composite pain scores measured by BPI
questionnaire, and quality of life assessments
(FACT-G questionnaire) did not show statistically
significant changes, but there was a trend towards
a decrease in the use of narcotic analgesics. There
was, however, no significant difference in analgesic
scores. A subgroup analysis of patients with an
analgesic score and pain score > 0 at the time of
screening, showed a trend towards improvement
for later infusions. However, given the study
limitations, such as small patient number, an
uncontrolled study design and short follow-up
period, these efficacy results need to be confirmed
with more robust studies. This first prospective
study evaluating the safety of zoledronic acid in
patients with hormone-refractory prostate cancer in
Korea is, however, noteworthy in providing
preliminary safety information.
The 3rd International Consultation on Prostate
Cancer developed a prostate cancer treatment
algorithm that supports the use of zoledronic acid
at first evidence of bone metastases.
29 Although
still controversial, it has been noted that
zoledronic acid stabilizes bones through an
increase in BMD as well as a delay of a mean time
to the onset of SREs, and prevents bone loss in
patients receiving ADT.
30 However, further
studies are needed to determine whether early
administration of zoledronic acid enhances the
effects of ADT or increases the survival rate in
prostate cancer patients with metastases. Promising
results, examining these issues, are anticipated
from a large clinical study currently underway.
In conclusion, Zoledronic acid, administered as
a 15-minute intravenous infusion in this study
demonstrated an acceptable and well-known
safety profile in patients with hormone refractory
prostate cancer with bone metastases. However, a
large, prospective, controlled study is necessary to
substantiate the efficacy of zoledronic acid in the
prevention of SREs, alleviation of pain and
improvement in quality of life.
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